Seems like a stretch to be comparing Anzalone and Leo... Leo was exceedingly clear about top line results for B in earlier pressers...clear enough that if he misrepresented one dose efficacy results CTIX would be buried under shareholder litigation...could you post the Anzalone representations you are referring to re: Arrowhead just in case I'm looking at a different set of facts?